-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Patient-Reported Outcomes in Hematology

Program: Education Program
Sunday, December 6, 2015: 9:30 AM-11:00 AM
W230, Level 2 (Orange County Convention Center)
Monday, December 7, 2015: 10:30 AM-12:00 PM
W224CDGH, Level 2 (Orange County Convention Center)

Description:

This educational session will focus on patient-reported outcomes and the importance of incorporating the patient perspective into healthcare. A patient reported outcome (PRO) is defined as the measurement of a patient’s perception of a health condition and its treatment. Examples of PROs include a patient’s report of functioning, pain or other symptoms, satisfaction, and sleep quality. Given the changing healthcare environment and an increased focus on comparative effectiveness research, it is even more important and sometimes essential to consider integrating PROs into both research and clinical care in hematology. This session will present information on the advances in measurement of PROs (NIH PROMIS), the integration of PROs in drug development and clinical care, and will highlight the use of PROs in clinical care for patients with chronic disease.

Dr. Cella will discuss how patient-reported outcome measures are developed with a focus on The Patient Reported Outcomes Measurement Information System (PROMIS). PROMIS is a measurement system that uses item response theory and that provides researchers and clinicians the ability to determine patient-reported outcomes using precise and reliable tools. Dr. David Cella will describe the capabilities of PROMIS for researchers and clinicians.

Dr. Catherine Acquadro will focus on the use of PROs in drug development with a focus in hematology. She will describe the advances in the assessment of PROs in clinical trials and provide an overview of regulatory issues to consider when using PROs in drug development.

Dr. Julie Panepinto will focus on the use of PROs in clinical care. She will focus on suggestions for implementation of PROs in a clinic setting and provide examples of how the use of PROs can lead to tailored care for an individual and ultimately improve patient outcomes.

Chair:
Ellen M. Werner, PhD, National Heart, Lung and Blood Institute, National Institutes of Health

Disclosures:
No relevant conflicts of interest to declare.

David Cella, PhD

Feinberg School of Medicine/Dept.of Medical Social Sciences, Northwestern University, Chicago, IL

Catherine Acquadro, MD

Mapi Research Trust, Lyon, France

Julie A. Panepinto, MD, MSPH

The Medical College of Wisconsin/Children's Research Institute of the Children's Hospital of Wisconsin, Milwaukee, WI

See more of: Education Program